Brief: Alligator Bioscience Announces Optimize-1 Trial Update; Cohort Fully Dosed With No Adverse Effects Reported
18/01/2022 07:20
Jan 18 (Reuters) - Alligator Bioscience AB ATORX.ST :
* ALLIGATOR BIOSCIENCE ANNOUNCES OPTIMIZE-1 TRIAL UPDATE:
COHORT
FULLY DOSED WITH NO ADVERSE EFFECTS REPORTED
Source text for Eikon: ID:nPn4dyljxa
Further company coverage: ATORX.ST
((reuters.briefs@thomsonreuters.com;))
Recent news on Alligator Bioscience AB
See all newsSweden's Alligator Bioscience Q3 sales fall as R&D winds down
Brief: Alligator Bioscience Q3 EBIT SEK -19.3 Million
Brief: Alligator Bioscience Appoints Johan Gileus As CEO
Brief: Alligator Bioscience Announces Final Outcome In Rights Issue
Brief: Alligator Bioscience To Initially Receive SEK 58.8 Mln From Rights Issue